Back to Search
Start Over
Influence of estrogen therapy on calcium, phosphorus, and other regulatory hormones in postmenopausal women: the MESA study.
- Source :
-
The Journal of clinical endocrinology and metabolism [J Clin Endocrinol Metab] 2013 Dec; Vol. 98 (12), pp. 4890-8. Date of Electronic Publication: 2013 Oct 03. - Publication Year :
- 2013
-
Abstract
- Background: Estrogen therapy (ET) is associated with lower serum calcium and phosphorus concentrations and is known to increase bone mineral density (BMD). Other biomarkers of mineral metabolism may help understand the biological basis of these actions.<br />Methods: We studied 2767 postmenopausal women in the Multi-Ethnic Study of Atherosclerosis, 862 (31%) of whom were using ET. We measured serum concentrations of calcium, phosphorus, 25-hydroxyvitamin D, 24,25-dihydoxyvitamin D, and fibroblast growth factor-23 and urinary fractional excretion of calcium (FEca) and phosphorus (FEphos). We examined the associations of ET with each biomarker. In addition, we tested whether the adjustment for biomarkers attenuated the association of ET with lumbar BMD measured by abdominal computed tomography in a subset of 810 women.<br />Results: In adjusted models, women who used ET were younger in age [62 (SD 8) vs 66 (9) y, P < .001], had lower mean serum calcium [-13 mg/dL (95% confidence interval [CI] -0.17, -0.10), P < .001] and lower FEca [-0.15% (95% CI -0.21, -0.09), P < .001]. Mean serum phosphorus was lower [-0.19 mg/dL (95% CI -0.23, -0.15), P < .001] and FEphos [0.56% (95% CI 0.16, 0.96), P = .007] was higher in women on ET. Mean 25-hydroxyvitamin D and 24,25-dihydroxyvitamin D were higher [1.52 ng/dL (95% CI 0.57, 2.47), P = .002, and 0.26 ng/mL (95% CI 0.03, 0.48), P = .03, respectively] in women who used ET. Mean PTH and fibroblast growth factor-23 did not differ significantly by the use of ET. ET use was strongly associated with higher lumbar BMD [12.75 mg/cm³ (95% CI 7.77-17.73), P < .001]; however, mineral metabolism measures did not meaningfully alter this association.<br />Conclusions: In a multiethnic cohort of postmenopausal women, ET use was associated with lower serum calcium, lower FEca, lower serum phosphorus, and higher FEphos, suggesting these associations are attributable to increased calcium intake into bone and increased urinary phosphorus excretion. ET use was also associated with greater concentrations of vitamin D metabolites. ET-associated differences in these mineral metabolism measures did not meaningfully attenuate the strong association between ET use and lumbar BMD.
- Subjects :
- 24,25-Dihydroxyvitamin D 3 blood
24,25-Dihydroxyvitamin D 3 metabolism
25-Hydroxyvitamin D 2 blood
25-Hydroxyvitamin D 2 metabolism
Aged
Aged, 80 and over
Biomarkers blood
Biomarkers metabolism
Biomarkers urine
Bone Density drug effects
Bone and Bones diagnostic imaging
Bone and Bones metabolism
Calcifediol blood
Calcifediol metabolism
Calcium urine
Cohort Studies
Cross-Sectional Studies
Ergocalciferols blood
Ergocalciferols metabolism
Female
Fibroblast Growth Factor-23
Humans
Middle Aged
Osteoporosis, Postmenopausal blood
Osteoporosis, Postmenopausal diagnostic imaging
Osteoporosis, Postmenopausal metabolism
Phosphorus urine
Radiography
Vitamin D blood
Vitamin D metabolism
Bone and Bones drug effects
Calcium blood
Estrogen Replacement Therapy
Fibroblast Growth Factors blood
Osteoporosis, Postmenopausal prevention & control
Phosphorus blood
Vitamin D analogs & derivatives
Subjects
Details
- Language :
- English
- ISSN :
- 1945-7197
- Volume :
- 98
- Issue :
- 12
- Database :
- MEDLINE
- Journal :
- The Journal of clinical endocrinology and metabolism
- Publication Type :
- Academic Journal
- Accession number :
- 24092825
- Full Text :
- https://doi.org/10.1210/jc.2013-2286